MA27848A1 - Formes posologiques d'azithromycine a effets secondaires reduits. - Google Patents

Formes posologiques d'azithromycine a effets secondaires reduits.

Info

Publication number
MA27848A1
MA27848A1 MA28638A MA28638A MA27848A1 MA 27848 A1 MA27848 A1 MA 27848A1 MA 28638 A MA28638 A MA 28638A MA 28638 A MA28638 A MA 28638A MA 27848 A1 MA27848 A1 MA 27848A1
Authority
MA
Morocco
Prior art keywords
azithromycin
glyceryl
effective amount
dosage form
mammal
Prior art date
Application number
MA28638A
Other languages
English (en)
Inventor
Avinash Govind Thombre
Leah Elizabeth Appel
Marshall David Crew
Dwayne Thomas Friesen
David Keith Lyon
Scott Baldwin Mccray
James Blair West
Scott Max Herbig
Julian Belknap Lo
Timothy Arthur Hagen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34468055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27848(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27848A1 publication Critical patent/MA27848A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 4 Décembre 2003 60/527,084 US 23 Janvier 2004 10/763,340 Voir en annexe le titre de l'invention et le texte de l'abrégé Formes posologiques d'azithromycine à effets secondaires réduits Une forme posologique orale comprenant de l??azithromycine et une quantité efficace d'un agent alcalinisant. De préférence, ladite forme posologique orale comprend une quantité efficace d'un agent alcalinisant et une forme en particules multiples d1azithromycine, ladite forme en particules multiples comprenant de l??azithromycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Habituellement, la forme posologique orale comprend n'importe quel moyen d'administration orale convenable tel qu'une poudre pour suspension orale, un paquet ou sachet de dose unitaire, un comprimé ou une capsule. Il est révélé en outre une suspension orale comprenant de l'azithromycine, une quantité efficace d'un agent alcalinisant et un véhicule. De préférence, l??azithromycine est une forme en particules multiples dans laquelle lesdites particules multiples comprennent de l'azithro-mycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Il est révélé également une méthode pour réduire les effets secondaires gastro-intestinaux, associés à l'administration d1azithromycine à un mammifère, comprenant l'administration de manière contigue d'azithromycine et d'une quantité efficace d'un agent alcalinisant audit mammifère, la fréquence des effets secondaires gastro-intestinaux étant inférieure à celle constatée en administrant une dose égale d'azithromycine sans ledit agent alcalinisant. Il est révélé en outre une méthode pour le traitement d'une infection par des bactéries ou des protozoaires chez un mammifère nécessitant un tel traitement, comprenant l'administration de manière contigue audit mammifère d'une dose unique d'une forme posologique orale, ladite forme posologique orale comprenant del??azithromycine et une quantité efficace d'un agent alcalinisant. Il est révélé en outre une forme en particules multiples d'azithromycine comprenant del??azithromycine, un agent tensio-actif et un support pharmaceutiquement acceptable.
MA28638A 2003-12-04 2005-12-08 Formes posologiques d'azithromycine a effets secondaires reduits. MA27848A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52708403P 2003-12-04 2003-12-04
US10/763,340 US6984403B2 (en) 2003-12-04 2004-01-23 Azithromycin dosage forms with reduced side effects

Publications (1)

Publication Number Publication Date
MA27848A1 true MA27848A1 (fr) 2006-04-03

Family

ID=34468055

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28638A MA27848A1 (fr) 2003-12-04 2005-12-08 Formes posologiques d'azithromycine a effets secondaires reduits.

Country Status (36)

Country Link
US (4) US6984403B2 (fr)
EP (1) EP1537859B1 (fr)
JP (2) JP4602711B2 (fr)
KR (1) KR100906290B1 (fr)
AR (1) AR045630A1 (fr)
AT (1) ATE407663T1 (fr)
BR (1) BRPI0403935B8 (fr)
CA (1) CA2467611C (fr)
CL (1) CL2004001501A1 (fr)
CR (1) CR7500A (fr)
CY (1) CY1108486T1 (fr)
DE (1) DE602004016444D1 (fr)
DK (1) DK1537859T3 (fr)
DO (1) DOP2004000994A (fr)
EA (1) EA010110B1 (fr)
ES (1) ES2312929T3 (fr)
GE (1) GEP20074056B (fr)
HK (1) HK1080367B (fr)
HR (1) HRP20040865A2 (fr)
IL (1) IL164165A (fr)
IS (1) IS2672B (fr)
MA (1) MA27848A1 (fr)
MX (1) MXPA04009424A (fr)
NL (1) NL1026315C2 (fr)
NO (1) NO20043903L (fr)
NZ (1) NZ535464A (fr)
OA (1) OA12858A (fr)
PA (1) PA8611501A1 (fr)
PE (1) PE20050573A1 (fr)
PL (2) PL1537859T3 (fr)
PT (1) PT1537859E (fr)
RS (1) RS84704A (fr)
SI (1) SI1537859T1 (fr)
TW (1) TWI351969B (fr)
UY (1) UY28509A1 (fr)
WO (1) WO2005053650A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0758244T4 (da) † 1994-05-06 2008-06-16 Pfizer Doseringsformer af azithromycin med styret frigivelse
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
WO2005053652A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
SI1691787T1 (sl) * 2003-12-04 2008-10-31 Pfizer Prod Inc Postopek za pripravo farmacevtskih produktov iz več delcev
DE602005003343T2 (de) * 2004-04-12 2008-09-11 Pfizer Products Inc., Groton Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
ATE529117T1 (de) * 2004-07-02 2011-11-15 Wakamoto Pharma Co Ltd Medizinische zusammensetzung auf wasserbasis mit azithromycin und herstellungsverfahren dafür
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060193908A1 (en) * 2004-11-09 2006-08-31 Burnside Beth A Extended release formulations of poorly soluble antibiotics
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
RU2443406C2 (ru) 2005-12-22 2012-02-27 Оцука Фармасьютикал Ко., Лтд. Способ получения содержащих лекарственное вещество восковых матричных частиц, экструдер для применения в способе и лекарственное средство с замедленным высвобождением, содержащее цилостазол
ZA200805793B (en) * 2005-12-22 2009-11-25 Otsuka Pharma Co Ltd Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
US20070281894A1 (en) * 2006-06-05 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
EP2091519B1 (fr) * 2006-11-30 2015-06-24 Bend Research, Inc Médicament enduit par vaporisation et polymère multiparticulaires sur un noyau pouvant fondre
JP5162134B2 (ja) * 2007-01-22 2013-03-13 愛媛県 機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品
EP2144599B1 (fr) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Granules à libération prolongée utilisant des matières cireuses
EP2134718A2 (fr) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Formes cristallines, et leurs utilisations
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
DE102007034155A1 (de) * 2007-07-21 2009-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Vorrichtung mit mindestens einer Verpackungseinheit mit einem zur Radiofrequenz-Identifikation dienenden RFID-Chip und Verfahren dazu
JP5468015B2 (ja) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
KR101367479B1 (ko) * 2008-07-21 2014-03-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 귀 질병 치료를 위한 제어 방출형 항미생물성 조성물 및 방법
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2314286A1 (fr) * 2009-10-21 2011-04-27 Ratiopharm GmbH Cinacalcet en granulés à fondre
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011125075A2 (fr) 2010-04-08 2011-10-13 Fdc Limited Nouveau système d'administration à rétention gastrique de macrolides
CN109106725A (zh) 2011-02-11 2019-01-01 Zs制药公司 用于治疗高钾血症的微孔性的硅酸锆
EP2714937B1 (fr) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
WO2013088274A1 (fr) 2011-12-14 2013-06-20 Wockhardt Limited Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
US9707255B2 (en) 2012-07-11 2017-07-18 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
WO2014066407A1 (fr) 2012-10-22 2014-05-01 ZS Pharma, Inc. Silicate de zirconium microporeux pour le traitement de l'hyperkaliémie
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
AU2014363929A1 (en) * 2013-12-10 2016-07-14 ZS Pharma, Inc. Zirconium silicate for treating hyperkalemia without co-administering lithium
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CN107427494A (zh) * 2015-03-10 2017-12-01 卢莫斯制药公司 环肌酸微混悬剂
JP6777734B2 (ja) 2015-06-10 2020-10-28 ピードモント アニマル ヘルス インコーポレイテッド 注射可能な抗生物質製剤及びその使用
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
HUE059630T2 (hu) 2016-03-15 2022-11-28 Acer Therapeutics Inc Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
EP3576755A4 (fr) * 2017-02-02 2020-12-02 McMaster University Bicarbonate à titre de potentialisateur d'agents antimicrobiens
BR112020015153A2 (pt) 2018-02-18 2021-01-05 G & G Biotechnology Ltd. Implantes com adesão aumentada ao invólucro
WO2020024060A1 (fr) 2018-08-01 2020-02-06 Mcmaster University Méthodes d'inhibition de la croissance microbienne
CN111643455A (zh) * 2020-06-22 2020-09-11 健民药业集团股份有限公司 一种阿奇霉素缓释干混悬剂及其制备方法
WO2022220669A1 (fr) * 2021-04-16 2022-10-20 Garcia Perez Miguel Angel Combinaison solide orale pour le traitement d'une infection virale
CN114699386B (zh) * 2022-04-14 2023-05-23 深圳职业技术学院 阿奇霉素组合物及其制备方法

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25342A (en) * 1859-09-06 Justus k
US26851A (en) * 1860-01-17 Improvement
US3590A (en) * 1844-05-17 Rule or measure
US228357A (en) * 1880-06-01 Walter m
US190365A (en) * 1877-05-01 Improvement in running-gear for vehicles
US6650A (en) * 1849-08-14 Edmund blunt
US14951A (en) * 1856-05-27 Boot-tree
US165563A (en) * 1875-07-13 Improvement in snow-plows
US2955956A (en) * 1957-05-15 1960-10-11 Morton Salt Co Process and apparatus for coating granules
US4092089A (en) * 1974-04-06 1978-05-30 Bayer Aktiengesellschaft Apparatus for the preparation of melt-sprayed spherical phenacetin granules
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
US4053264A (en) * 1976-01-30 1977-10-11 United Technologies Corporation Apparatus for making metal powder
US4293570A (en) * 1979-04-02 1981-10-06 Chimicasa Gmbh Process for the preparation of sweetener containing product
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4675140A (en) * 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4874611A (en) 1985-06-20 1989-10-17 The Dow Chemical Company Microencapsulated ant bait
US5100592A (en) * 1986-03-12 1992-03-31 Washington University Technology Associated, Inc. Method and apparatus for granulation and granulated product
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5456932A (en) 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (fr) 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
JPH03206039A (ja) * 1990-01-08 1991-09-09 Kyoto Yakuhin Kogyo Kk ニフェジピン持続性製剤
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
EP0452862B1 (fr) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Noyaux des germes sphériques, granules sphériques et procédé de leur préparation
US5183690A (en) * 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
GB9014646D0 (en) 1990-07-02 1990-08-22 Courtaulds Coatings Holdings Coating compositions
US5194262A (en) * 1990-10-22 1993-03-16 Revlon Consumer Products Corporation Encapsulated antiperspirant salts and deodorant/antiperspirants
US5196199A (en) * 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US5292657A (en) * 1990-12-31 1994-03-08 Pioneer Hi-Bred International, Inc. Process for preparing rotary disc fatty acid microspheres of microorganisms
US5143662A (en) * 1991-02-12 1992-09-01 United States Surgical Corporation Process for preparing particles of bioabsorbable polymer
US5707546A (en) * 1991-06-17 1998-01-13 Rio Linda Chemical Co., Inc. Generation and storage of chlorine dioxide in a non-aqueous medium
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
GB9201857D0 (en) * 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4214272A1 (de) * 1992-05-04 1993-11-11 Nukem Gmbh Verfahren und Vorrichtung zur Herstellung von Mikrokugeln
CA2095776C (fr) * 1992-05-12 2007-07-10 Richard C. Fuisz Compositions a base de polydextrose, facilement dispersables
DK0641195T3 (da) * 1992-05-22 1996-08-05 Goedecke Ag Fremgangsmåde til fremstilling af lægemiddelblandinger med forsinket virkning
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
TW271400B (fr) * 1992-07-30 1996-03-01 Pfizer
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
US5569467A (en) 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
US5690959A (en) 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
US5935600A (en) * 1993-09-10 1999-08-10 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing comestible unit and product therefrom
US5597416A (en) * 1993-10-07 1997-01-28 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
CA2185803C (fr) * 1994-03-18 2006-07-11 Edward M. Rudnic Systemes d'administration de medicaments emulsionnes
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DK0758244T4 (da) * 1994-05-06 2008-06-16 Pfizer Doseringsformer af azithromycin med styret frigivelse
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5582855A (en) 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5601761A (en) * 1994-09-26 1997-02-11 The Dow Chemical Company Encapsulated active materials and method for preparing same
US5493044A (en) * 1994-10-20 1996-02-20 Fmc Corporation Process for preparing alkylsilyl or arylsilyl ethers
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
FR2732621B1 (fr) * 1995-04-10 1997-06-06 Rhone Poulenc Chimie Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention
EP0826376B1 (fr) 1995-05-02 2007-01-24 Taisho Pharmaceutical Co. Ltd Composition s'administrant par voie orale
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5883103A (en) * 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
US5855915A (en) * 1995-06-30 1999-01-05 Baylor University Tablets or biologically acceptable implants for long-term antiinflammatory drug release
EP0784933A3 (fr) * 1995-10-16 1997-11-26 Leaf, Inc. Libération prolongée d'additifs dans des produits comestibles
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
US6139872A (en) 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
TW474824B (en) * 1996-09-13 2002-02-01 Basf Ag The production of solid pharmaceutical forms
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
DE19652257A1 (de) * 1996-12-16 1998-06-18 Lohmann Therapie Syst Lts Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
JP2002522354A (ja) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ，インコーポレイテッド 固溶体ビードレット
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
JP4546643B2 (ja) * 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
JPH11335300A (ja) * 1998-05-20 1999-12-07 Sumitomo Pharmaceut Co Ltd グリセリン脂肪酸エステルを使用した徐放性製剤
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
CA2245398C (fr) * 1998-08-21 2002-01-29 Apotex Inc. Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
US6165512A (en) 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
IL143376A0 (en) * 1998-11-30 2002-04-21 Teva Pharma Ethanolate of azithromycin, process for the manufacture, and pharmaceutical compositions thereof
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU7719100A (en) * 1999-09-27 2001-04-30 Panayiotis Constantinides Compositions of tocol-soluble therapeutics
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
JP2005515212A (ja) * 2001-12-21 2005-05-26 ファイザー・プロダクツ・インク アジスロマイシンの湿式造粒法
KR100676025B1 (ko) * 2002-02-01 2007-01-29 화이자 프로덕츠 인코포레이티드 아지쓰로마이신의 건조 과립화 제제
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7572773B2 (en) * 2003-07-24 2009-08-11 Pliva Hrvatska D.O.O. Single dose fast dissolving azithromycin

Also Published As

Publication number Publication date
EP1537859A3 (fr) 2005-07-06
HK1080367A1 (en) 2006-04-28
CR7500A (es) 2007-09-03
RS84704A (sr) 2007-02-05
EA010110B1 (ru) 2008-06-30
CA2467611A1 (fr) 2005-06-04
US20080015343A1 (en) 2008-01-17
DK1537859T3 (da) 2008-11-17
GEP20074056B (en) 2007-03-12
PA8611501A1 (es) 2005-08-04
BRPI0403935A (pt) 2005-08-09
HK1080367B (zh) 2010-11-05
TWI351969B (en) 2011-11-11
JP4602711B2 (ja) 2010-12-22
EP1537859B1 (fr) 2008-09-10
OA12858A (en) 2006-09-15
NL1026315C2 (nl) 2006-01-24
CA2467611C (fr) 2010-03-30
PL379984A1 (pl) 2006-11-27
BRPI0403935B1 (pt) 2018-02-06
IS2672B (is) 2010-09-15
CL2004001501A1 (es) 2005-05-13
HRP20040865A2 (en) 2006-02-28
BRPI0403935B8 (pt) 2021-05-25
IL164165A (en) 2012-01-31
JP2005162733A (ja) 2005-06-23
JP2010132700A (ja) 2010-06-17
CY1108486T1 (el) 2014-04-09
EP1537859A2 (fr) 2005-06-08
EA200401216A1 (ru) 2005-12-29
WO2005053650A1 (fr) 2005-06-16
WO2005053650A8 (fr) 2005-12-01
KR100906290B1 (ko) 2009-07-06
NZ535464A (en) 2009-03-31
TW200518784A (en) 2005-06-16
US20060039988A1 (en) 2006-02-23
MXPA04009424A (es) 2005-07-26
IL164165A0 (en) 2005-12-18
US20050123627A1 (en) 2005-06-09
US20060029677A1 (en) 2006-02-09
ES2312929T3 (es) 2009-03-01
NL1026315A1 (nl) 2005-06-07
DE602004016444D1 (de) 2008-10-23
PE20050573A1 (es) 2005-09-05
UY28509A1 (es) 2005-07-29
PL1537859T3 (pl) 2009-01-30
IS7464A (is) 2005-06-05
US6984403B2 (en) 2006-01-10
PT1537859E (pt) 2008-11-18
ATE407663T1 (de) 2008-09-15
NO20043903L (no) 2004-11-09
SI1537859T1 (sl) 2008-12-31
KR20060033851A (ko) 2006-04-20
DOP2004000994A (es) 2005-06-30
AR045630A1 (es) 2005-11-02

Similar Documents

Publication Publication Date Title
MA27848A1 (fr) Formes posologiques d'azithromycine a effets secondaires reduits.
Hollander et al. Pharmacotherapy for obsessive-compulsive disorder
Armoiry et al. Lenalidomide in the treatment of multiple myeloma: a review
Thanacoody Thioridazine: resurrection as an antimicrobial agent?
Kishimoto et al. Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage.
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
DE69832712D1 (de) Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
WO2005065069A3 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
Baguley et al. DMXAA: an antivascular agent with multiple host responses
US6616925B1 (en) Combined preparation for the treatment of neoplasic diseases or of infectious diseases
WO2017042944A1 (fr) Agent thérapeutique ou méthode de traitement pour la leucémie lymphoïde aiguë (lla) à chromosome philadelphie positif (ph+)
Dutta et al. Morphine modulation of toll-like receptors in microglial cells potentiates neuropathogenesis in a HIV-1 model of coinfection with pneumococcal pneumoniae
KR20060109493A (ko) 비만을 치료하기 위한 조합 약물 치료
JP2008540405A5 (fr)
US20030232874A1 (en) Methods and compositions for the treatment of chronic lymphocytic leukemia
US4906646A (en) Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
CA2563058A1 (fr) Traitement de soutien d'une maladie du foie
TNSN05319A1 (fr) Formes posologiques d'azithromycine a effets secondaires reduits
Niu et al. Nardosinone suppresses RANKL-induced osteoclastogenesis and attenuates lipopolysaccharide-induced alveolar bone resorption
Hiraoka et al. Effects of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice
Celegato et al. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma
KR101686917B1 (ko) 라세탐 및 카르니틴을 포함하는 약학 조성물 및 그의 제조방법
FR3056108B1 (fr) Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif
Kahan Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus
ZA200507322B (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system